Stocktoria
Pulmatrix, Inc. PULM
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-03-21
Pulmatrix, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | $7.8M | $7.3M | $6.1M | $5.2M |
| R&D expense | $38,000 | $7.2M | $15.5M | $18.2M | $15.4M |
| Operating income | -$5.2M | -$9.8M | -$14.7M | -$18.9M | -$20.2M |
| Income tax | $0 | — | — | — | — |
| Net income | -$5.2M | -$9.6M | -$14.1M | -$18.8M | -$20.2M |
| EPS (diluted) | $-1.41 | $-2.62 | $-3.87 | $-5.46 | — |
| Operating cash flow | -$5.4M | -$10.7M | -$16.0M | -$19.4M | -$19.7M |
| Free cash flow | — | -$11.1M | -$16.7M | -$19.4M | -$19.9M |
| Cash & equivalents | $4.1M | $9.5M | $19.2M | $35.6M | $53.8M |
| Total assets | $4.1M | $9.9M | $34.0M | $41.0M | $58.8M |
| Total liabilities | $329,000 | $996,000 | $16.0M | $9.8M | $11.4M |
| Shareholders' equity | $3.8M | $8.9M | $18.0M | $31.1M | $47.4M |
Source: SEC EDGAR filings · CIK 0001574235 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.